9M 2023 Financial Overview

9M 2023: R&D update New data confirm Vyepti's long-term benefits and effectiveness Extension results presented at AHS 65th annual scientific meeting 22 22 BL 1-12 13-24 Study weeks 25-36 37-48 49-60 61-72 0+ Placebo-controlled period Long-term extension period (all patients received eptinezumab) 30 LS mean change from baseline -25 20 10 -10 5 -30 -Epti 100 mg to 100 mg (n=286; BL=47.3) Epti 300 mg to 300 mg (n=282; BL=43.4) -Placebo to Epti 100 mg (n=144; BL=42.7) -Placebo to Epti 300 mg (n=146; BL=37.6) n=840 CM or EM Starling, A et al. Long-term effectiveness of eptinezumab in patients with prior preventive migraine treatment failures. Poster presentation #114 at the 65th Annual Scientific Meeting of the American Headache Society (AHS) June 15-18, 2023, in Austin, Texas. CM/EM: chronic/episodic migraine 1) NCT04418765 • Phase IIIb DELIVER trial¹) Evaluating the safety and efficacy of Vyepti in hard to-treat patients with 2-4 previous treatment failures, including open label extension phase Extension phase confirm long- lasting migraine preventive effects and strong tolerability profile • Vyepti treatment for up to 18 months: • Reduced number of migraine days • Reduced severity of headaches Reduced use of acute medication

View entire presentation